MedTrace Logo

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma

NCT07019181 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-06-13

No results posted yet for this study

Summary

Evaluating the rate of pathologic complete remission in patients with squamous esophageal cancer treated perioperatively with tislelizumab in combination with chemotherapy

Conditions

  • Esophagus Cancer

Interventions

DRUG

Tislelizumab

Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks

DRUG

albumin-bound paclitaxel

albumin-bound paclitaxel 260mg/m2，day 1 of every 3 weeks

DRUG

Nedaplatin

Nedaplatin 80mg/m2，day 1 of every 3 weeks

Sponsors & Collaborators

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-30
Primary Completion
2025-12-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07019181 on ClinicalTrials.gov